Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04370288 |
Recruitment Status : Unknown
Verified April 2020 by Daryoush Hamidi Alamdari, Mashhad University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : April 30, 2020
Last Update Posted : May 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Covid-19 | Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine) | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients |
Actual Study Start Date : | April 19, 2020 |
Estimated Primary Completion Date : | September 20, 2020 |
Estimated Study Completion Date : | September 21, 2020 |
Arm | Intervention/treatment |
---|---|
No Intervention: Control group
Covid-19 patients treated with standard medical therapy (supportive therapy).
|
|
Experimental: Intervention group
Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
|
Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
A mixture of MCN will be injected to covid-19 patients.
Other Name: Leucomethylene Blue |
- Proportion of patients remaining free of need for mechanical ventilation in both groups [ Time Frame: Day 7 ]All patient will be assess for changes in disease severity.
- Mortality rate in both groups [ Time Frame: Day 28 ]
- Improvement in Pa02/Fi02 ratio in both groups [ Time Frame: Day 2 ]
- Duration of hospital stay in both group. [ Time Frame: Day 28 ]
- Duration of Intensive Care Unit stay in both groups [ Time Frame: Day 28 ]
- Days free of dialysis in both groups [ Time Frame: Day 28 ]
- C-reactive proteins [ Time Frame: 3-5 Days ]
- WBC Count [ Time Frame: 3-5 Days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed case of Covid-19 (by RT-PCR, HRCT)
- Admission to Intensive Care Unit
- Need for intubation and mechanical ventilation (PaO2/FiO2 < 100-200)
- Written informed consent
Exclusion Criteria:
- Pregnancy and breastfeeding
- History of G6PDH deficiency
- Preadmission anticoagulation
- Severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
- Medical records of cirrhosis
- Active chronic hepatitis
- Severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit
- Patients with history of allergic reaction or significant sensitivity to Methylene blue
- Treatment with immunosuppressive agents
- Use of other investigational drugs in the moment of inclusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04370288
Contact: Daryoush Hamidi Alamdari, Ph.D | +98 51 3882 8574 | hamidiad@mums.ac.ir | |
Contact: Amir Yarahmadi, Ph.D | +98 51 3882 8574 | yarahmadiA961@mums.ac.ir |
Iran, Islamic Republic of | |
Imam Reza Hospital | Recruiting |
Mashhad, Razavi Khorasan, Iran, Islamic Republic of, 9137913316 | |
Contact: Ahmad Bagheri Moghaddam, M.D 05138412081 bagheria@mums.ac.ir |
Principal Investigator: | Daryoush Hamidi Alamdari, Ph.D | Mashhad University of Medical Sciences, Mashhad, Iran |
Responsible Party: | Daryoush Hamidi Alamdari, Associate professor, Mashhad University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT04370288 |
Other Study ID Numbers: |
IR.MUMS.REC.1399.122 |
First Posted: | April 30, 2020 Key Record Dates |
Last Update Posted: | May 4, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Informed Consent Form (ICF) Clinical Study Report (CSR) |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Covid-19 Coronavirus |
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Acetylcysteine |
N-monoacetylcystine Methylene Blue Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers Antidotes Enzyme Inhibitors |